These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38900699)

  • 21. The CDC Domestic Mpox Response - United States, 2022-2023.
    McQuiston JH; Braden CR; Bowen MD; McCollum AM; McDonald R; Carnes N; Carter RJ; Christie A; Doty JB; Ellington S; Fehrenbach SN; Gundlapalli AV; Hutson CL; Kachur RE; Maitland A; Pearson CM; Prejean J; Quilter LAS; Rao AK; Yu Y; Mermin J
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):547-552. PubMed ID: 37200231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.
    Fink DL; Callaby H; Luintel A; Beynon W; Bond H; Lim EY; Gkrania-Klotsas E; Heskin J; Bracchi M; Rathish B; Milligan I; O'Hara G; Rimmer S; Peters JR; Payne L; Mody N; Hodgson B; Lewthwaite P; Lester R; Woolley SD; Sturdy A; Whittington A; Johnson L; Jacobs N; Quartey J; Ai Payne B; Crowe S; Elliott IA; Harrison T; Cole J; Beard K; Cusack TP; Jones I; Banerjee R; Rampling T; ; Dunning J
    Lancet Infect Dis; 2023 May; 23(5):589-597. PubMed ID: 36566771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical considerations on monkeypox antiviral medications: An overview.
    Pourkarim F; Entezari-Maleki T
    Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of tecovirimat in subjects with Mpox.
    Tempestilli M; Mondi A; D'Avolio A; Forini O; Pinnetti C; Mazzotta V; Gagliardini R; Beccacece A; De Nicolò A; Faccendini P; Cimini E; Maggi F; Girardi E; Nicastri E; Boffito M; Vaia F; Antinori A
    Int J Antimicrob Agents; 2024 Feb; 63(2):107068. PubMed ID: 38141836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mpox Genital Lesions: A Large Single-center Experience With Intermediate Follow-up.
    Lee J; McLean J; Zucker J; Brandes S; Joice G
    J Urol; 2023 Sep; 210(3):510-516. PubMed ID: 37294043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monkeypox Virus (MPXV) Infection: A Review.
    Kumari R; Arya P; Yadav SP; Mishra RC; Yadav JP
    Infect Disord Drug Targets; 2024; 24(4):76-82. PubMed ID: 38243966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging pharmacological strategies for treating and preventing mpox.
    Grosenbach DW; Russo AT; Blum ED; Hruby DE
    Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Pilot of an Mpox Severity Scoring System.
    Zucker J; McLean J; Huang S; DeLaurentis C; Gunaratne S; Stoeckle K; Glesby MJ; Wilkin TJ; Fischer W; Damon I; Brooks JT
    J Infect Dis; 2024 Mar; 229(Supplement_2):S229-S233. PubMed ID: 37956401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mpox Surveillance Based on Rash Characteristics - 13 Emergency Departments, United States, June-December 2023.
    Berdahl CT; Krishnadasan A; Pathmarajah K; Moran GJ; Torres JR; Waxman M; Mower W; Garner OB; Duvergne LP; Rimoin AW; Gorbach PM; Talan DA;
    MMWR Morb Mortal Wkly Rep; 2024 Jun; 73(22):507-513. PubMed ID: 38843078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Healing Corneal Ulcer and Uveitis Following Monkeypox Disease: Diagnostic and Therapeutic Challenges.
    Androudi S; Kaufman AR; Kouvalakis A; Mitsios A; Sapounas S; Al-Khatib D; Schibler M; Pineda R; Baglivo E
    Ocul Immunol Inflamm; 2024 Apr; 32(3):253-258. PubMed ID: 37140328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.
    Mazzotta V; Cozzi-Lepri A; Lanini S; Mondi A; Carletti F; Tavelli A; Gagliardini R; Vita S; Pinnetti C; Aguglia C; Colavita F; Faccendini P; Matusali G; Faraglia F; Beccacece A; Paulicelli J; Girardi E; Nicastri E; Vaia F; Maggi F; Antinori A
    J Med Virol; 2023 Jun; 95(6):e28868. PubMed ID: 37306318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System.
    Vo C; Zomorodi R; Silvera R; Bartram L; Lugo LA; Kojic E; Urbina A; Aberg J; Sigel K; Chasan R; Patel G
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad552. PubMed ID: 38023539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public-private hospital partnership during the 2022 NYC mpox outbreak.
    Mgbako O; Chan J; Pitts RA; DiLorenzo MA; Knutsen D; Mazo D
    Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e110. PubMed ID: 37502253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA.
    Lash MK; Latham NH; Chan PY; Foote MMK; Garcia EA; Silverstein MF; Wong M; Alexander M; Alroy KA; Bajaj L; Chen K; Howard JS; Jones LE; Lee EH; Watkins JL; McPherson TD
    Emerg Infect Dis; 2023 Nov; 29(11):2353-2357. PubMed ID: 37796277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addressing mpox at a Frontline Community Health Center: Lessons for the Next Outbreak.
    Allan-Blitz LT; Khan T; Elangovan K; Smith K; Multani A; Mayer KH
    Public Health Rep; 2024; 139(3):294-300. PubMed ID: 37846528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Tecovirimat Therapy With Mpox Symptom Improvement: A Cross-sectional Study-King County, Washington, May-October 2022.
    Karmarkar EN; Golden MR; Kerani RP; Pogosjans S; Chow EJ; Bender Ignacio RA; Ramchandani MS; Kay MK; Cannon CA; Dombrowski JC
    Open Forum Infect Dis; 2024 Mar; 11(3):ofae029. PubMed ID: 38456195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
    Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Countering Mpox Vaccination Disparities in Los Angeles County, California, May-December 2022.
    Brihn A; Yeganeh N; Kulkarni S; Moir O; Madrid S; Perez M; Singhal R; Kim AA
    Am J Public Health; 2023 Dec; 113(12):1258-1262. PubMed ID: 37733994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monkeypox: A re-emerging disease.
    Kaur N; Dabar J; Bassi P
    Indian J Pharmacol; 2024 Mar; 56(2):129-135. PubMed ID: 38687317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
    Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
    J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.